Recruiting

Fractional Ablative Laser

Sponsor:

Sciton

Code:

NCT06389071

Conditions

Lichen Sclerosus Lesion

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

Fractional 2940 nm Laser

Study Details

Brief summary:

Fractional ablative laser treatment for Lichen Sclerosus lesion

Conditions

Lichen Sclerosus Lesion

Study ID

NCT06389071

Start date

Mar 1, 2024

Status verified date

Apr, 2026

Completion date

Dec 30, 2027

Anticipated

Primary completion date

Jul 20, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Female aged 18 years or older
  • Biopsy-proven vulvar lichen sclerosus lesion
  • Experiencing one or more of the following symptoms of LS:

1. Dryness
2. Itching
3. Burning
4. Bleeding
5. Blistering
6. Soreness
7. Easily bruises
8. Easily tears
9. Ulcerated lesions
10. Painful intercourse
  • Negative urine pregnancy test if subject is of childbearing potential before enrollment
  • Absence of vulvovaginal infection i.e. fungi, bacterial vaginosis, and STI
  • Ability to understand and sign informed consent, questionnaires, and all investigation requirements
  • Willing to consent to clinical photographs of the treatment area
  • Willing to consent to ultrasound images of the treatment area
  • Willing and able to logistically follow schedule of treatments and follow-up visits

Exclusion Criteria:

  • Pregnancy, less than 3 months postpartum, or planning to become pregnant during the investigation to protect integrity of the data
  • Is a nursing mother
  • History of uncontrolled malignant disease
  • Active urogenital infection or chronic infection (i.e., candida, herpes, herpes simplex, bacterial vaginosis, trichomoniasis, or other infection)
  • Immunocompromised (e.g., lymphoma, AIDS, Wiskott-Aldrich syndrome)
  • Subjects with genital skin disease, psoriasis due to risk of koeberizing
  • Subjects on immunosuppressants: mycophenolate, retinoids, azathioprine, cyclosporin
  • Known allergy or intolerance to local anesthesia
  • Known history of connective tissue disease
  • Known propensity for keloid formations
  • Known medical condition that may affect wound healing
  • Any reason that the investigator deems prohibits participation in the investigation

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Treatment + PRP Arm

active comparator: Treatment only Arm

Interventions

Fractional 2940 nm Laser

Fractional 2940 nm Laser

Primary outcome measure

  • Histological clearance [ Time Frame: 16 weeks ]

Central Contacts and Locations

Locations

Clinique Medicale Uro-Gyneco de l'Abitibi

Recruiting

Val-d'Or, Quebec, Canada, J9P1W1

Contacts

Josee Parent, MD

819-825-3800

More Information

Sponsor

Sciton

Last update posted

Apr 23, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Sciton on 2026-04-23.